Biotech Values

[Aiming4]

Dew - no, I don't think the article was designed to pump COR, the focus was on Gary Lynch and his research.

I'd also guess the financing terms were already set before the article was published.

No fun for COR longs today, but perhaps a buying opportunity.

In fact, barring disclosure of any bad news for CX717 or Cortex underlying this financing, I'd guess buying COR under $2 will prove to be a great investment within a few months.

Great as in 100% or more returns.